Anti-Theranos: FDA Approval In Hand, Sight Diagnostics Aims At $2.7 Billion Blood Testing Giant, Sysmex [Forbes]
SYSMEX CORP UNSP/ASDR (SSMXY)
NASDAQ:AMEX Investor Relations:
sysmex.co.jp/en/ir/index.html
Company Research
Source: Forbes
Anti-Theranos: FDA Approval In Hand, Sight Diagnostics Aims At $2.7 Billion Blood Testing Giant, Sysmex Sysmex Reuters Sysmex did not respond to repeated requests for comment. Sysmex is growing and profitable — enjoying a 14% net profit margin. Its revenues for the year ending March 2019 were $2.7 billion — up 4.1% from the prior year. Sysmex earned net income of $378 million up 5.3% from the year before, according to its 2019 annual report Sysmex is not alone in this industry. Rivals include bioMerieux, Haemonetics, Bio-Techne, Autobio Diagnostics, Guardant Health, Biocept, Epigenomics, Siemens Healthineers, Becton Dickinson, and Danaher. Here’s how OLO works. It takes two drops of blood, turns it into a high resolution image, and analyzes the image to perform a complete blood count (CBC) – analyzing the number of a patient's red and white blood cells by type and the number of platelets. This is an $8 billion market in the U.S.. where 500 million CBC tests are conducted each year. Gl
Show less
Read more
Impact Snapshot
Event Time:
SSMXY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SSMXY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SSMXY alerts
High impacting SYSMEX CORP UNSP/ASDR news events
Weekly update
A roundup of the hottest topics
SSMXY
News
- Sysmex America Begins Selling Hemostasis Instruments and Reagents Under the Sysmex Brand in the United StatesPR Newswire
- Asia-Pacific Next-Generation IVD Market Report 2023-2033: Molecular Diagnostics, Genomics, and Next-Generation Sequencing (NGS) are Anticipated to Play Pivotal Roles in Future Growth [Yahoo! Finance]Yahoo! Finance
- Asia-Pacific's Next-Generation IVD Market Worth $42+ Billion by 2033: Key Insights by Type, End-user and Country [Yahoo! Finance]Yahoo! Finance
- Asia-Pacific Measurable/Minimal Residual Disease (MRD) Testing Market Analysis 2023-2033 - Medicare Expansion and Rising Consumer Awareness Driving Growth [Yahoo! Finance]Yahoo! Finance
- Asia-Pacific MRD Testing Research Report 2024: Market to Grow by Over $1 Billion to 2033, Driven by Precision Medicine Revolution in Early Detection [Yahoo! Finance]Yahoo! Finance